The AT1R antagonists significantly decreased the level of angiotensin II-induced ESCC cell proliferation (P<0.05, Figure 3B), whereas the AT2R antagonist had no effect (P>0.05, Figure 3B). This evidence concerns the gene AGTR1 and esophageal squamous cell carcinoma.